Here's a question - The head of the FDA Dr. Hahn has suggested that a 35% reduction rate in mortality is the gold standard. Would Cytodyn be willing to submit for an EUA if leronlimab surpassed that 35% but was slightly under the DSMC predetermined p value for mortality?

Since Mulholland will be screening the questions I don't think anything of real value will actually be answered.